Clinical investigation of entecavir combined with adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B cirrhosis

Abstract

Objective To investigate the clinical effect of entecavir combined with adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B cirrhosis, to provide a reference for clinical treatment. Methods 117 cases of liver cirrhosis with lamivudine resistance were selected, they were divided into the control group and the observation group according to treatment.60 cases in the observation group used entecavir and adefovir combination therapy, 57 cases in the control group was given lamivudine combined with adefovir dipivoxil.The HBeAg conversion rate, HBV-DNA negative rate, liver function, liver function Child-pugh score were compared between two groups. Results After treatment for 24 weeks, 48 weeks, the HBV-DNA negative conversion rates in the observation group were 75.00%, 95.00%, which were higher than those in the control group, the differences were statistically significant (χ2=4.251, P=0.024; χ2=4.535, P=0.018). In the observation group, ALB, ALT, TBiL, PT improved better than the control group, the differences were statistically significant(t=4.229, P=0.025; t=6.214, P=0.008; t=5.514, P=0.014; t=5.233, P=0.017). After treatment, CTP of the observation group was (7.15 ± 1.05) points, which was significantly lower than the control group (8.86 ± 1.47) points, the difference was statistically significant (t=5.874, P=0.010). The incidence rate of adverse reactions between the two groups showed no statistically significant difference(P>0.05). Conclusion Entecavir combined with adefovir dipivoxil therapy has good effect for lamivudine-resistant liver cirrhosis, which will help to improve liver function, inhibit HBV replication, it is worthy of clinical application. Key words: Liver cirrhosis; Entecavir; Adefovir dipivoxil; Lamivudine